TrialBlood2016

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Benjamin L Lampson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.